Abstracts by key term: chemotherapy
To date, there are only a few studies in Germany that examine the reality of iron deficiency/anemia treatment for tumor patients who are undergoing chemotherapy. As part of a European prospective observational study, a prevalence of anemia of 40% (at the start of the study) and 67% (during the course of the study) was measured in over 15,000 tumor patients in 2001/02. In addition, the proportion of patients with anemia therapy and the distribution of the different therapy options were recorded. Of these patients, almost 40% were treated with antianemic preparations, with ESA having the highest proportion among the treatment options (Ludwig et al. 2004). In addition, Steinmetz and colleagues (2016) collected data from almost 1,000 cancer patients in Germany regarding demographic and disease-specific characteristics as well as the distribution of antianemic treatment options. It was found that the majority of patients received blood transfusions to treat the anemia and that both ESA and IV iron played a rather minor role in the treatment. The aim of this cohort study is therefore to investigate the care situation of patients with tumor disease and iron deficiency/anemia therapy. In order to better understand the reality of care in Bavaria (1/7 of those insured by statutory health insurance (GKV) in Germany), patient characteristics and disease-specific therapy options were analyzed using diagnostic and billing data as part of a PHARAO project run by the Bavarian Association of Statutory Health Insurance Physicians (KVB). analyzed.